Uno Healthcare

UNO HEALTHCARE was established in 1996 as a pharmaceutical...

Our products

See our complete line and contact us

Contact Us

Please Contact us and our specialized team will answer you promptly

Monthly News Roundup – February 2015

Sanofi Receives FDA Approval for Basal Insulin Toujeo The U.S. Food and Drug Administration has approved Sanofi’s Toujeo (insulin glargine [rDNA origin], a once-daily long-acting basal insulin for adults with type 1 or type 2 diabetes. In the clinical trials evaluating Toujeo, all of the primary study endpoints were met by demonstrating similar blood sugar control with Toujeo as compared

Monthly News Roundup – March 2015

FDA Approves First Biosimilar Product Zarxio On Friday, March 6th the U.S. Food and Drug Administration (FDA) approved Sandoz’s Zarxio (filgrastim-sndz), the first U.S. approved biosimilar. Zarxio, the biosimilar for Amgen’s filgrastim (Neupogen), is a recombinant granulocyte colony-stimulating factor used to boost white blood cells after cancer treatments. Biological products are generally derived from a living organism, including humans,

Cholesterol in Eggs May Not Hurt Heart Health: Study

TUESDAY Feb. 16, 2016, 2016 — The once-maligned egg may not be a heartbreaker after all, new research suggests. Finnish say that even carriers of a gene — called APOE4 — that increases sensitivity to dietary cholesterol don’t seem to have anything to fear when it comes to the impact of eggs, or any other

FDA Approves Taltz

FDA Approves Taltz (ixekizumab) for Plaque Psoriasis March 22, 2016 — The U.S. Food and Drug Administration today approved Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches of skin redness and flaking. Psoriasis is an autoimmune disorder that occurs more commonly in patients with a family history of

FDA Approves Cinqair

FDA Approves Cinqair (reslizumab) to Treat Severe Asthma March 23, 2016 — The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite

FDA Approves Defitelio

FDA Approves Defitelio (defibrotide sodium) for Hepatic Veno-Occlusive Disease Following Hematopoietic Stem-Cell Transplantation March 30, 2016 — The U.S. Food and Drug Administration today approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or

Monthly News Roundup – March 2016

FDA Approves Teva’s Cinqair to Treat Severe Asthma In March, the U.S. Food and Drug Administration (FDA) approved Teva’s Cinqair (reslizumab) as an adjunct for the maintenance treatment of severe asthma in adults not well-controlled on their current asthma medications. Cinqair is an interleukin 5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) given once every four weeks via infusion in a clinical

Social Groups May Lengthen Retirees’ Lives

TUESDAY Feb. 16, 2016, 2016 — Staying socially active by joining book clubs or church groups may add years to your life after retirement, a new study suggests. The more groups a person belongs to in early retirement, the lower their risk of premature death, Australian researchers found. The chance of dying within six years

FDA Expands Use of Xalkori (crizotinib) to Treat ROS-1 Positive Non-Small Cell Lung Cancer

March 11, 2016 — The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC. Lung cancer is the leading cause of cancer-related deaths in the United

Health Tip: Pay Attention While Walking

— Walking while distracted can be as dangerous as distracted driving. To avoid walking while distracted, the American Academy of Orthopaedic Surgeons advises: If you’re listening to a radio, phone or music player, lower the volume so you can hear surrounding noise and nearby traffic. Move away from pedestrian traffic if you need to make

FDA Approves Imbruvica (ibrutinib) for the First-Line Treatment of Chronic Lymphocytic Leukemia

NORTH CHICAGO, Ill., March 4, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).1 The approval is based on data from the randomized, multi-center, open-label Phase 3 RESONATE™-2 (PCYC-1115) trial, which evaluated

FDA Approves Evomela

FDA Grants Spectrum Pharmaceuticals Approval of Evomela (melphalan) for Injection HENDERSON, Nev., March 15, 2016 –(BUSINESS WIRE)–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted approval of Evomela for

FDA Approves Kovaltry

FDA Approves Bayer’s Kovaltry (Antihemophilic Factor (Recombinant)) for the Treatment of Children and Adults with Hemophilia A WHIPPANY, N.J., March 17, 2016 /PRNewswire/ — The U.S. Food and Drug Administration has approved Bayer’s Kovaltry Antihemophilic Factor (Recombinant), an unmodified, full-length factor VIII compound for the treatment of hemophilia A in children and adults. The approval

Monthly News Roundup – February 2016

Briviact Wins FDA Approval As Adjunct for Partial Onset Seizures Epilepsy is a brain disorder that causes people to have recurring seizures, consisting of uncontrollable muscle movements, abnormal sensations or thinking. The U.S. Food and Drug Administration (FDA) has approved Briviact (brivaracetam) as an add-on treatment for partial onset seizures in patients age 16 years and older with epilepsy. Briviact (brivaracetam)

Health Tip: Is Your Child Stressed?

— Children and teens aren’t immune to stress. But can parents recognize the warning signs? The American Psychological Association mentions these potential symptoms: Acting moody or withdrawn. Having sleep or appetite changes. Clinging to parents. Avoiding activities that used to excite the child. Complaining frequently of headache or stomachache without an apparent cause. Behaving unusually

FDA Approves Odefsey

FOSTER CITY, Calif.–(BUSINESS WIRE)–Mar. 1, 2016– Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Emtricitabine and tenofovir alafenamide are from Gilead Sciences and rilpivirine is from Janssen

FDA Approves Xeljanz XR

Pfizer Announces FDA Approval of Xeljanz XR (tofacitinib citrate), the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis February 24, 2016 — Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Xeljanz XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment of moderate to severe rheumatoid arthritis (RA) in

FDA Approves Briviact

February 19, 2016 — The U.S. Food and Drug Administration yesterday approved Briviact (brivaracetam) as an add-on treatment to other medications to treat partial onset seizures in patients age 16 years and older with epilepsy. Epilepsy is a brain disorder that causes people to have recurring seizures. A seizure is an episode, usually of relatively short duration,

Pfizer Receives Expanded FDA Approval For Ibrance (palbociclib) In HR+, HER2- Metastatic Breast Cancer

Friday, February 19, 2016 — Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of Ibrance (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. Now Ibrance also is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-)

Monthly News Roundup – January 2016

Merck’s Once-Daily Zepatier for Hepatitis C Wins Approval Hepatitis C virus (HCV) affects over 3 millions Americans, and may lead to liver impairment, cirrhosis or even liver failure. In January, the U.S. Food and Drug Administration (FDA) approved the oral treatment Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis Cvirus (HCV) genotypes 1 (the

Health Tip: Let Kids Prepare Breakfast

— Breakfast is the most important meal of the day, and it’s a good idea to have kids create their own nutritious start. The Academy of Nutrition and Dietetics offers these ideas for what to include: A slice of whole-wheat toast, served with a slice of cheese and 100 percent whole-fruit juice. Milk with iron-fortified

FDA Approves Expanded Use of Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

PRINCETON, N.J., February 5, 2016 –(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today that Daklinza (daclatasvir, 60 mg), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) in combination with sofosbuvir (with or without ribavirin) in genotypes 1 and 3. The expanded label includes data in three additional challenging-to-treat

FDA Approves Two Supplemental Indications for Harvoni in Chronic Hepatitis C Patients With Advanced Liver Disease

FOSTER CITY, Calif.–(BUSINESS WIRE)–Feb. 16, 2016– Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved additional indications for Harvoni (ledipasvir/sofosbuvir) for use in chronic hepatitis C patients with advanced liver disease. Harvoni in combination with ribavirin (RBV) for 12 weeks was approved for use in chronic hepatitis